Aurobindo Pharma on track to develop complex products, expand global footprint

"In the US, around 220 abbreviated new drug applications (ANDAs) are awaiting final approval..With the pandemic situation easing, your company will resume its development trajectory, with a focus on developing a product range of complicated injectables," it informed shareholders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rI4Ktxe
via IFTTT